Aldosterone Synthase Inhibitors (ASI)

Future Strategies to Prevent Heart Failure

by Prateek Chopra | May 22, 2026 | Cardiology Conferences | ESC-HF 2026 Heart failure (HF) prevention is increasingly focused on early intervention targeting cardiometabolic, inflammatory, renal, and neurohormonal pathways before the development of symptomatic disease. Emerging evidence suggests that integrated preventive strategies can substantially reduce incident HF, cardiovascular (CV) events, and progression of chronic kidney disease (CKD). The findings were […]

Mineralocorticoid Receptor Blockers and Aldosterone Synthase Inhibitors: Competitors or Allies in Primary Aldosteronism?

by Prateek Chopra | June 4, 2026 | Cardiology Conferences | ESH 2026 Clinical Context: Non-steroidal mineralocorticoid receptor antagonists (MRAs) and aldosterone synthase inhibitors (ASIs) are emerging therapeutic approaches in primary aldosteronism (PA). Evidence from randomized trials, single-arm studies, real-world analyses, and ongoing clinical programs evaluates the efficacy, biochemical outcomes, and safety of finerenone, baxdrostat, and dexfadrostat. Key Evidence – MRAs:

Mineralocorticoid Receptor Blockers and Aldosterone Synthase Inhibitors: Competitors or Allies in Primary Aldosteronism? Read Post »

Leave a Comment / ESH Day 1 / bluetree.healthcare@gmail.com / July 29, 2026 / Aldosterone Synthase Inhibitors (ASI), Finerenone, Non-Steroidal Mineralocorticoid Receptor Antagonists (MRAs), Primary Aldosteronism, Resistant Hypertension